Tag

Argenx

All articles tagged with #argenx

pharmaceuticals2 years ago•2 min saved

Immunovant's Autoimmune Drug Surges, Beating Expectations

Immunovant's experimental drug, IMVT-1402, has shown promising results in lowering immunoglobulin G (IgG) levels in healthy adults, indicating its potential to treat various autoimmune conditions. The drug led to dose-dependent reductions in IgG without causing negative effects on LDL cholesterol or serum albumin levels. Immunovant's stock soared to a two-year high following the announcement, while shares of Argenx, a competitor with its drug Vyvgart, slipped. Although Argenx currently has a lead in development across rare diseases, analysts believe Immunovant's drug could have implications for self-administered injections in treating rheumatoid arthritis.

via Investor's Business Daily|

#argenx #autoimmune-conditions #immunovant

business2 years ago•0 min saved

Argenx Raises $1.1B in Global Offering Following Positive Trial Results

Dutch biotech company Argenx launched a $750 million offering after sharing promising Phase II data for its only approved drug, which is being tested as a treatment for a rare neurological disorder. Investment firm Baillie Gifford Overseas Limited has expressed interest in purchasing up to $200 million in shares as part of the offering. Argenx's shares rose approximately 6% in trading following the announcement.

via Endpoints News|

#argenx #biotech #business

health2 years ago•0 min saved

"Promising Results: Argenx Drug Slows Nerve Disorder Progression"

Belgian drugmaker Argenx announced that its antibody treatment, Vyvgart, significantly delayed the progression of chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune nerve disorder that causes loss of feeling and muscle strength in the arms and legs. In a Phase 3 clinical trial, Vyvgart demonstrated a 61% reduction in the risk of relapse compared to a placebo, achieving the trial's main goal.

via STAT|

#argenx #autoimmune-nerve-disorder #health

healthcare2 years ago•10 min saved

"Positive Results for Argenx's VYVGART Hytrulo in Nerve Disorder Study"

Zai Lab and argenx have announced positive topline results from the ADHERE study, which evaluated VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. The therapy showed a 61% reduction in the risk of relapse and a favorable safety profile. Detailed data from the study will be presented at an upcoming medical meeting. CIDP is a rare autoimmune disease that affects the peripheral nervous system, causing weakness and sensory dysfunction in the limbs.

via Yahoo Finance|

#argenx #chronic-inflammatory-demyelinating-polyneuropathy-cidp #clinical-trial

healthcare2 years ago•0 min saved

FDA approves subcutaneous injectable for myasthenia gravis treatment.

The FDA has approved a new injectable version of argenx's autoimmune disease drug Vyvgart, marketed as Vyvgart Hytrulo, for people with generalized myasthenia gravis. The condition causes a person's immune system to make antibodies that attack their muscles, making movement, speaking, and swallowing difficult and life-threatening when it impedes breathing. The new version will be available in July.

via Endpoints News|

#argenx #autoimmune-disease #fda

biopharma2 years ago•7 min saved

Genmab CEO sees M&A potential in new partnership with Argenx for antibody discovery.

Genmab, a Danish antibody specialist with a $27 billion market cap, has announced a multi-year research deal with Dutch drugmaker argenx to enter the immunology and inflammation market. The companies will split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time. Genmab CEO Jan van de Winkel touts M&A potential as the company expands beyond oncology.

via Endpoints News|

#argenx #biopharma #genmab